Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119529 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06119529 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT06119529, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG LY3872386
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06119529
The ClinicalTrials.gov registry entry for NCT06119529 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06119529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06119529 about?
NCT06119529 is a clinical study titled "A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis". The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY387238...
What is the current status of trial NCT06119529?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-11-01. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT06119529?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), LY3872386 (DRUG).
Who is sponsoring clinical trial NCT06119529?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.